There were no statistically significant differences in the degree

There were no statistically significant differences in the degree of positive staining of the various integrins examined in the cardiovascular system before and after LVAD support. The results obtained were similar in tissues obtained from IHD patients and from DCM patients. Perlecan was expressed on the membrane of the cardiomyocytes (Fig. 2). In both patient groups, the expression in the pre-LVAD situation was significantly less than in the controls. Only in IHD patients LVAD support resulted in some increase; however, the expression remained below control levels. Messenger RNA expression of integrin-α1, -α3, -α5, -α6, -α7, -α10, -α11, -β1, -β3, -β5, and -β6 were tested by Q-PCR.

Statistically significant

changes in mRNA expression due to LVAD support were only observed in 5 out of 11 integrins tested (Fig. 3) in either one or both patient groups. However, these 5 integrins did not show significant differences PLX3397 nmr with the healthy controls (both pre- and post-LVAD) except for integrin-α6 in DCM patients. In this case the pre-LVAD level is significantly lower than control mTOR activity level (Fig. 3). Expression of integrin-α1, -α6 and -α10 mRNA significantly increased after LVAD support in DCM patients compared to pre-LVAD. The observed increase was 0.98-fold (P=.014), 1.40-fold, (P=.007), and 2.47-fold (P=.023), respectively. In IHD patients significant increases in mRNA expression were seen after LVAD support for integrin-α6 and -β6; 23-fold (P=.046) and 9.34-fold (P=.026), respectively, whereas a decrease (0.41-fold, P=.039) was measured for integrin-α5. Integrins mediate interactions between cells, basal membrane and the extracellular matrix (ECM) that are essential for several out cellular processes. Intact integrin function has been related to anti-apoptotic signaling and cell survival [16], induction of post-infarct cell migration and

myocardial repair [17], activation and regeneration involving epithelial–mesenchymal transition [18], as well as to a normal progression of cardiomyocytes through the cell cycle [19]. Structural remodeling of the ventricular wall in patients with heart failure involves changes in the ECM [5], [6] and [20], cardiomyocytes, and basal membranes [13]. The changes observed in the patient group of this study were the same as described by Bruggink et al. [13] and [20]. Since integrins form the contact between cells and their surrounding matrix and are important in the mechanotransduction of the contracting cardiomyocytes, it might be expected that if changes in the ECM occur this will be reflected in integrin expression in the myocardium. Furthermore, it has been described that LVAD support in heart failure patients leads to at least partial normalization of the heart condition [8] and [9] among others reflected in changes in regulatory miRNA expression [7].

This is a collaboration between the Novartis Vaccines Institute f

This is a collaboration between the Novartis Vaccines Institute for Global

Health, Swiss Tropical and Public Health Institute, Kenyan Medical Research Institute and Wellcome Trust Sanger Institute and [grant number 251522]. The funding source had no involvement in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; or in the decision to submit the article for publication. “
“Acute diarrhea (AD) is a frequent cause of child hospitalization and outpatient visits in children under 5 years [1]. In Brazil, before introduction of the rotavirus vaccine in 2006, about 120.000 hospitalizations a year occurred due to AD in children under five years (DATASUS/Ministry of Health of Brazil, 2006). Rotavirus is the leading cause of severe acute diarrhea in children in developed and in developing countries and is the Capmatinib major cause of death in poor countries [2] and [3]. Seven groups of rotavirus have been identified (A to G) and group A (RV-A) is responsible for more than 90% of human rotavirus infections [4]. RV-A has great genetic diversity due almost 60 serotypes (G and P) and the most common strains are: G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] [5]. In Brazil, between 12% and 42% of children under 5 years with diarrhea

had positive stool samples for RV-A before the KU-57788 datasheet introduction of the RV-A vaccine. This increased from 22% to 38% in children hospitalized for AD [6] and [7]. More than 51 genotype combinations were reported and the most common genotypes described were G1P[8], G9P[8] and G2P[4] [8]. Vaccination is the better measure to prevent rotavirus [1], [2] and [9] and its adoption has been recommended by World Health Organization [10]. An attenuated monovalent

human RV-A (G1P[8] strain; Rotarix®) and a pentavalent bovine-human reassortant (G1,G2,G3, G4 and P[8] strains; RotaTeq®) are licensed worldwide. Rotarix® was introduced in the Brazilian National Immunization Program Adenylyl cyclase (BNIP) in 2006 in a two-dose schedule at 2 and 4 months of age and co-administered with tetravalent, pneumococcal and poliovirus vaccines. RV-A vaccine efficacy against severe RV-A AD varied between more than 90% Europe and Asia, 85% in Latin America, 72% in South Africa to 49% in Malawi [11], [12], [13] and [14]. Three case–control studies carried out in a high income country (Belgium) [15] and in low to middle-income countries (El Salvador and Bolivia) [16] and [17] found a two-dose vaccine effectiveness of 90%; 76% and 77% respectively and a one-dose effectiveness of 91%; 51% and 56% respectively against hospitalization by RV-A AD. In Brazil, two small case controls studies showed a range of 40–85% effectiveness in preventing hospitalization caused by G2P[4] [18] and [19]. The reason for variation in vaccine protection is not clear and has been attributed to antigen diversity, malnutrition and higher incidence of other enteric pathogens [20].

The F0 subunit of the ATPase is a hydrophobic membrane-embedded p

The F0 subunit of the ATPase is a hydrophobic membrane-embedded proton channel encoded by genes atpBEF. The F1 subunit constitutes the catalytic ATPase, encoded by atpHAGDC [19] and [21]. The first gene in the operon, atpI, has no defined function and does not appear to form part of the F0F1 ATPase complex [22]. This genetic organisation is conserved between E. coli and S. Typhimurium. A comprehensive identification of genes required for S. Typhimurium infection of mice by our laboratory identified mutation of atpA as an attenuating lesion [23]. A defined atpA deletion mutant was subsequently confirmed to be attenuated for growth in vivo and furthermore was found to offer significant protection against

subsequent LGK-974 concentration challenge [23]. Here we present a full analysis of the role of the F0F1 ATPase in S. Typhimurium infection and the potential use of mutants in the atp operon as live attenuated vaccines. The bacterial strains and plasmids used in this study are shown in Table 1. Bacteria were grown at 37 °C in Luria–Bertani (LB) broth or on LB agar. Media were supplemented beta-catenin signaling with antibiotics

where stated, at the following concentrations, kanamycin 50 μg/ml, ampicillin 100 μg/ml and chloramphenicol 25 μg/ml. Minimal medium (used to determine carbon source utilisation) consisted of M9 salts (Sigma Dorset UK) supplemented with 0.1 mM CaCl2, 1 mM MgSO4, 4 μg/ml histidine and the stated carbon source at 0.4% (final w/v). Oligo-directed mutagenesis (ODM), an adaptation of ET-cloning, was used to replace the target genes on the Salmonella chromosome with a kanamycin resistance cassette flanked with FRT regions from pBADkanFRT [24] and [25]. PCR was used to amplify the kanamycin resistance FRT cassette with 5′ and 3′ 60 bp arms homologous to DNA flanking the target genes (see Table 2 for primer sequences). S. Typhimurium LB5010 containing pBADλred was grown in

LB broth supplemented with ampicillin to an OD595 of 0.25. Arabinose was added to 0.2% (final only w/v) to induce red gene expression. Cultures were grown to OD595 0.5 and electroporated with the purified ODM PCR product described above. Mutant colonies were selected on LB agar plates supplemented with 50 μg/ml kanamycin. The desired allelic replacement of the target genes was confirmed by PCR (see Table 2 for primer sequences). Mutations in S. Typhimurium LB5010 were transduced into SL1344 by bacteriophage P22 as described previously [26] with selection on LB agar plus kanamycin and gene deletions were confirmed to be correct by PCR and sequencing. The kanamycin resistance FRT cassette was then excised to leave only a 128 bp FRT scar site. Briefly, electrocompetent mutants of SL1344 were transformed with pCP20 [24] grown at 30 °C and then plated onto LB agar containing 100 μg/ml ampicillin. Single colonies were grown in LB at 39 °C (to prevent replication of pCP20) for 6 h then diluted and plated onto LB agar and incubated overnight at 39 °C.

We agree with the comment in Kleiman, Shah, and Morganroth (2014)

We agree with the comment in Kleiman, Shah, and Morganroth (2014), that “[computer models]… need to be standardized, regulated and widely available before they are adopted to support sponsor and regulatory decisions”. It is sensible to ask “which

ion channels should we screen”? We consider important factors in the answer to this in the sections below. For our output of interest, how much can block of a particular channel influence the predictions? In this case, we are interested in predicting APD changes, it is evident from Fig. 2 that (depending on the model choice) IKr, ICaL and perhaps IKs block could have large effects on APD. At the degree of block likely to be encountered, block of (solely) INa and Ito have much less impact than those of the other channels, and so a choice could be made not to screen these. But more mechanistic predictions of pro-arrhythmic risk, Adriamycin other than simply APD prolongation, may be sensitive to the apparently-small changes we observed. Indeed, sodium channel blockers have been seen to prolong the QRS complex, potentially leading to increased pro-arrhythmic risk via conduction slowing or block, rather than delayed repolarisation (Gintant, Gallacher, & Pugsley, 2011). It is also worth noting that APD is not a linear function of channel block — blockade of INa and Ito could have large effects when another channel

is also being blocked. A more ‘global’ evaluation of the simulation output’s sensitivity to each channel block (under the influence of different combinations of block on the other channels) would be needed before concluding a channel cannot significantly see more found influence the outcome of interest. In contrast, additional ion channels — such as IK1 — can have a large effect on the action potential (Fig. 2). But these channels may not be blocked by a large enough proportion of compounds to consider screening them as standard, as discussed below. Some ion channels, pumps and exchangers are historically blocked by very few compounds. The outcome of ‘missing an effect’ in these rare cases is likely to be no more severe than progressing such a compound to later,

more expensive, safety testing, and picking up the effect there. The economic cost of screening for additional effects on such ion currents may therefore outweigh the cost of missing an ion current effect. There is also the variability, sensitivity and specificity of such screens to consider. In the case of an ion channel being blocked by as few as 1 in 10,000 compounds, the chance of a positive screening result being a ‘false positive’ is likely to far outweigh the chance of it being a ‘true positive’. A cost benefit analysis could be performed for each ion channel screening assay, based on: its variability, sensitivity and specificity; historical compound liability; and the cost of ‘missing’ an adverse interaction with this channel, and progressing to the next stage of testing.

The reliance on big pharma alone to develop new vaccines is chang

The reliance on big pharma alone to develop new vaccines is changing with the emergence of public–private partnerships. These partnerships, which engage public health institutions, donor agencies

and academia, as well as the pharmaceutical industry, have the potential to create a new era for vaccine development. The PATH Malaria Vaccine Initiative is a successful demonstration of a partnership between an NGO, industry, academia, donors and government. It encompasses the development GDC-0068 molecular weight of RTS,S malaria vaccine candidates, translational research and demonstration projects. The vaccine investment strategy that has been undertaken by GAVI to evaluate the feasibility and cost effectiveness of introducing malaria vaccine within the next 5 years gives the partnering pharmaceutical companies an indication of the kind of advance market commitment that can be generated through GAVI support. Another example

of a successful partnership is the Meningitis Vaccine Project that involved WHO and PATH with support from the Bill and Melinda Gates Foundation. Not only did the scientists develop an effective and safe MenA conjugate vaccine, but the commitment of African governments within the meningitis belt to roll out the vaccine resulted in a dramatic reduction of Group A meningitis infections to almost negligible levels within a three year period. With BI 2536 manufacturer their confidence boosted by this success, the countries involved are now aiming to eliminate Group A meningitis much infection across the Meningitis Belt. The GVAP calls for the use of a new model to assist decision-makers in prioritising investments in new vaccine; the model is based on health, economic, demographic,

programmatic, and social impact criteria as well as scientific, technical and business opportunities. The data presented to the WHO’s STI Vaccine Consultation critically evaluated the potential for the development of vaccines to prevent infection from five common STI pathogens, namely herpes simplex virus, Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, or Trichomonas vaginitis and/or the diseases they cause. The data unequivocally showed that development of vaccines to prevent all five infections could be justified using the GVAP criteria. Significant scientific advances have been made towards the development of vaccines for these five infections, development in herpes and chlamydial vaccine being the most advanced. Furthermore, the pharmaceutical industry has demonstrated interest in investing in the field.

clinicaltrials gov/ct2/show/NCT00981695?term=MVA HIVA+and+pedvacc

clinicaltrials.gov/ct2/show/NCT00981695?term=MVA.HIVA+and+pedvacc&rank=1 The Pan African

Clinical Trials Registry (PACTR2009010001152787) http://www.pactr.org/ATMWeb/appmanager/atm/atmregistry?_nfpb=true&_windowLabel=basicSearch_1_2&basicSearch_1_2_actionOverride=%2Fpageflows%2Ftrial%2FbasicSearch%2FviewTrail&basicSearch_1_2id=115. “
“The majority of high income countries have Navitoclax introduced three-dose routine human papillomavirus (HPV) vaccination programmes [1]. Although most countries are vaccinating girls/women, only the US, Australia and one Canadian province (Prince Edward Island) have included boys in their routine HPV vaccination programmes. The most commonly used HPV vaccine in high

income countries (including Canada, the UK, the US and Australia) BIBW2992 mouse is the quadrivalent [1], which protects against HPV-16/18 (responsible for more than 70% of cervical cancers [2] and associated with other anogenital [3] and [4] and head and neck cancers [5]) and HPV-6/11 (associated with more than 85% of anogenital warts [6]). Although vaccinating girls against HPV is expected to dramatically reduce the burden of HPV-associated diseases [7] and [8] and to be highly cost-effective [9], [10] and [11], it nevertheless imposes an important financial strain on immunisation budgets. In Canada, HPV vaccine represents 40% of the total cost to fully immunise a girl from infancy to adolescence (Dr. Bruno Turmel, Quebec Ministry of Health and Social Services, Personal communication) [12]. Decision-makers may thus be interested in the possibility of reducing doses of HPV vaccine to invest the funds on improving coverage to underserved populations, male HPV vaccination or other immunisation programmes. Recent evidence suggests that two doses of HPV vaccine may be as protective as three doses in the short-term. A nested nonrandomised before analysis within a phase III randomised clinical trial in Costa Rica suggested that two doses of HPV vaccine has similar high efficacy against vaccine-type persistent

infections as three doses, four years after vaccination [13]. More recently, a phase III randomised trial examined the immunogenicity of two doses in girls 9–13 years compared to three doses in girls 9–13 years and three doses among young women 16–26 years. Results from the study showed that antibody responses for the vaccine-types among girls (9–13 years) who received two doses were noninferior to those among young women (16–26 years) who received three doses, over a period of three years after the last vaccine dose [14]. However, antibody responses to HPV-18 at two years and HPV-6 at three years were significantly lower for girls (9–13 years) who received two doses vs. girls (9–13 years) who received three doses.

The number of eyes that met the criteria for rescue therapy durin

The number of eyes that met the criteria for rescue therapy during the study period was significantly higher in the IV bevacizumab group (n = 9) compared with the IV ranibizumab group (n = 4) (P = .042; paired t test). A multivariate

analysis comparing BCVA and central subfield thickness outcomes between the IV bevacizumab and IV ranibizumab groups, taking into account number of injections, baseline BCVA, and central subfield thickness, demonstrated a statistically significant influence of baseline BCVA on follow-up BCVA (P < .001) but no other significant differences between groups (P = .051) across follow-up time (P = .490) regarding these 2 outcomes. There was no significant DAPT solubility dmso change in mean intraocular pressure compared RO4929097 with baseline at any of the study follow-up visits in either group (P < .05). In the IV bevacizumab group, 1 patient experienced clinically significant cataract progression that prevented a clear view of the fundus after his ninth visit and another patient developed transient vitreous hemorrhage after an acute posterior vitreous detachment. There were 2 patients who developed endophthalmitis in the IV ranibizumab group (both patients were treated unilaterally) and 1 patient, also in the IV ranibizumab

group, who experienced increased blood pressure, controlled with oral most antihypertensive agents. Additionally, 1 patient developed transient worsening of renal function. This patient, who had the right eye treated with ranibizumab and the left eye treated with bevacizumab, had a serum creatinine level of 2.0 mg/dL at baseline and, during the study, his creatinine level increased to 2.9 mg/dL; at the last study visit, his creatinine level had returned to 2.0 mg/dL. No patient experienced

myocardial infarction, stroke, or gastrointestinal bleeding throughout the study period. In the present study, both groups achieved significant improvement in BCVA compared with baseline at all study visits (P < .05). At week 48, there was a mean BCVA improvement of 0.23 logMAR (∼11 letters) and 0.27 logMAR (∼13 letters) in the IV bevacizumab and IV ranibizumab groups, respectively. Similarly, DRCR.net 12 reported a mean BCVA improvement of 8.2 letters in patients with DME treated with IV ranibizumab plus prompt laser and 8.4 letters in patients treated with IV ranibizumab plus deferred laser after 1 year of follow-up. More recently, the RISE and RIDE 13 studies also showed significant improvements in BCVA associated with IV ranibizumab treatment for DME. In the RISE study, the IV ranibizumab 0.5 mg group demonstrated a mean improvement of 12 letters in BCVA at 1 year, and in the RIDE study, the IV ranibizumab 0.5 mg group demonstrated a mean improvement of 11 letters in BCVA at 1 year.

Serum glucose was estimated

Serum glucose was estimated Venetoclax by Oxidase method.17 The activities of serum AST and ALT were assayed by Reitman and Frankel method.18 Total cholesterol19 and triglycerides20 were determined by the respective method. Liver was dissected out and washed in normal saline and stored −80 °C for assay of glycogen content by using Anthrone reagent.21 Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by student’s‘t’ test. The values are mean ± SD for six rats in each group. Statistical significance was considered at

p < 0.05. There was a significant elevation of serum glucose, total cholesterol, triglycerides, aspartate transaminase, alanine transaminase while liver glycogen significantly decreased in the diabetic control rats as compared with non-diabetic control group. Table 1 showed the blood glucose levels of the control, Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) at different time points (0, 30, 60, 120, 150 min) after oral administration of glucose (2 g/kg). There was a peak increase in the blood glucose at 30 min in all the groups. In Glibenclamide and 400 mg of MEDH treated group, there was a decrease in blood glucose level at 150 min when compared to control group. Table 2 showed the level of blood GDC-0449 mw glucose in euglycemic rats at 0, 1, 2 and 4 h of administration. The administration of Glibenclamide (7 mg/kg)

and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) on euglycemic rats was not significant at

1 h, while it was significant at 4 h (p < 0.05) as compared to control. The level of blood glucose in normal and diabetic rats at 0, 1, 2 and 4 h of administration was showed in Table 3. There was a significant elevation of blood glucose level in diabetic group as compared to normal control rats. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) reduced the blood glucose in diabetic rats as compared to control rats. The 4th day treatment with Glibenclamide and 400 mg of MEDH resulted in significant hypoglycemic effect in diabetic group. Table 4 showed the level of serum AST and ALT and liver glycogen in normal and experimental rats. There was a Terminal deoxynucleotidyl transferase significant elevation of serum AST and ALT and decrease in liver glycogen content in diabetic control as compared to non-diabetic control rats. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) significantly decreased AST and ALT levels and increased glycogen content in diabetic rats as compared to control rats. There was a significant increase in the cholesterol and triglycerides in diabetic rats as compared to control. The administration of Glibenclamide (7 mg/kg) and methanolic extract of D. hamiltonii (200 mg and 400 mg/kg) brought back the levels of cholesterol and triglycerides to near normal rats ( Table 5).

It will therefore be critically important to highlight the need f

It will therefore be critically important to highlight the need for screening, particularly for unvaccinated women, in materials sent with future screening invitations to these cohorts. Of course, this study measured screening intention almost 10 years before girls were due to be invited, and it is unclear to what extent this will reflect their future behaviour. The findings relating to ethnicity are also concerning, particularly as fewer women from non-white ethnic backgrounds tend to be screened for cervical cancer selleck inhibitor in the UK and elsewhere [6] and [44]. Rates of cervical cancer in women from black and Asian backgrounds have

been found to be higher than for white women in the 65+ age-group [45]. Incidence in women under 65 is currently lower among Asian women but is similar among black and white women, so lower vaccine uptake in black girls is of particular concern. Uptake may be low in non-white ethnic groups due to cultural barriers and parental concerns that vaccination may encourage sexual activity [46]. Studies have suggested the role of social sources of information and discussion (e.g. hearing about the HPV vaccine and discussing it with family or friends) are important for increasing perceived vaccine effectiveness [47] and increasing requests for the

vaccine [48]. This supports previous research showing cues to action (e.g. a recommendation from friends, family or a doctor) are the strongest predictors of vaccine uptake [49]. These factors should be taken into consideration when developing PD-0332991 in vitro health promotion campaigns

(e.g. narrative leaflets) aimed at reducing ethnic inequalities in vaccine uptake. As increasing numbers of countries, the including the UK, move to a two-dose HPV vaccine schedule [50], ethnic inequalities might be reduced. Research in the US has shown that ethnic disparities occur mainly between initiators and completers, with those from non-white ethnic backgrounds being equally likely to initiate but less likely to complete the three dose course [51]. As we had a single response category for ‘1–2’ doses, we were unfortunately unable to explore predictors of receipt of two or more doses in our sample. This study benefited from a large sample size, including girls from a variety of ethnic and socioeconomic backgrounds. Response rates in both waves of data collection were very high at over 98% but we acknowledge that there could be systematic differences between the schools that readily agreed to take part in the study and those that refused or failed to respond to our initial contact. In addition, a significant number of girls were absent at the point of data collection or did not know their vaccine status, which may reduce the generalisability of the findings. Because recruitment was limited to London, and to schools with levels of vaccine coverage within 10% of the national average, the results may not be generalisable to England more widely or to schools where uptake is much higher or lower.

To determine acute oral toxicity, the method of acute oral toxici

To determine acute oral toxicity, the method of acute oral toxicity at fixed doses was used.13 The extract was administered at doses of 5 mg/kg to 100 mg/kg, with animals showing no notable signs of toxicity. The 50% lethal dose was found to be greater than 100 mg/kg,

which is twice the highest dose (50 mg/kg) used for evaluation of a possible diuretic effect. Animals were maintained under standard condition of temperature and humidity and underwent for an adaptation period of three days. The animals were divided into four groups (n = 6). Group 1, as the negative control, received normal saline solution (25 ml/kg oral administration); group 2 received the reference diuretic, furosemide (Lasix, SANOFI-AVENTIS) at 20 mg/kg administered intraperitoneally E7080 in vitro 14 and 15; groups 3 and 4 received the ethanolic extract of G. seemannii Peyr. at 25 mg/kg p.o. and 50 mg/kg p.o. respectively, in normal saline solution (25 ml/kg p.o.) and the diuretic activity was carried out based on the method of Lipschitz et al. 16 Immediately after administration

by gavage using an 18 G intragastric cannula, the animals were placed in metabolic cages (1 per cage), especially designed to separate urine and feces, and kept at a controlled temperature of 22–25 °C. At the end of 12 h, the volume of urine collected was measured. During this period, no food and water was available to the animals. During the two-week experimental period, the parameters measured were body weight (before and after the

test period), total urine volume, and concentration selleck of Na+, K+ and Cl− in the urine. Na+, K+, Cl− concentrations were enough determined by an ion sensitive electrode (Roche Hitachi 917) automatic analyzer. After the experiment, animals were sacrificed by ether anesthesia.17 Results are expressed as the mean ± SEM. Data was analyzed by one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. A value of p < 0.001 was considered statistically significant. The LD50 was estimated to be greater than 100 mg/kg. The experimental extracts of G. seemannii Peyr. were used in concentrations of 25 mg/kg and 50 mg/kg, with animals showing no signs of acute toxicity. No macroscopic alterations were noted in the viscera of the treated rats. The animals were observed with no signs of dehydration at 12 h intervals. The reference diuretic (furosemide) significantly increased urine output compared to the control (p > 0.001), with a diuretic index of 2.86. Administration of the test drug at 25 and 50 mg/kg also resulted in a significant increase in urine volume, although less than that found with the reference drug. The diuretic index for these two doses was 1.49 and 1.75, respectively, compared to 2.86 found for furosemide ( Table 1). Ethanolic extract of G. seemannii Peyr.